Immunogenicity of Streptococcus equi subsp. equi recombinant SeM protein and bacterin in mice

ABSTRACT: The infection caused by Streptococcus equi, known as strangles, affects the respiratory system of horses, causing high morbidity and rapid spread among the herd. Bacterin vaccines, composed of inactivated whole cells of S. equi, have variable efficacy and duration. Infected animals produce specific antibodies against SeM, the immunodominant antigen of S. equi. This makes it a promising target for vaccine development. In this context, the objective of this work was to evaluate a vaccine combining S. equi bacterin and recombinant SeM protein. Mice were vaccinated with bacterin (S. equi ~1.2 × 108CFU/ml); rSeM protein (20g); bacterin-rSeM combination; or PBS (Control Group) and challenged with a suspension of S. equi, containing 10 × LD50. All vaccinated mice survived the challenge and produced anti-rSeM and anti-S. equi antibodies, which were assessed by indirect ELISA. The Control Group reached endpoint criteria 96 h after infection. These results demonstrate that a vaccine combining the S. equi bacterin with rSeM protein protects mice against strangles. This combination vaccine could potentially protect horses and overcome the limitations of currently available strangle vaccines.

RESUMO: A infecção causada por Streptococcus equi, denominada adenite, atinge o sistema respiratório de equinos, causando alta morbidade e rápida disseminação entre o rebanho. Vacinas bacterinas, compostas de células inteiras inativadas de S. equi apresentam eficácia e duração variáveis. Animais infectados apresentam anticorpos específicos à proteína SeM, antígeno imunodominante de S. equi, o que a torna um alvo promissor para o desenvolvimento de vacinas. Neste contexto, o objetivo deste trabalho foi avaliar uma vacina baseada na administração simultânea da bacterina e da proteína SeM recombinante. Camundongos foram vacinados com a bacterina (S. equi ~1.2 × 108CFU/ml); a proteína rSeM (20g); a bacterina e rSeM simultaneamente; ou PBS (Grupo Controle) e, posteriormente, foram desafiados com uma suspensão de S. equi contendo 10 × LD50. Todos os animais vacinados apresentaram anticorpos anti-rSeM e contra S. equi, avaliados através de ELISA indireto, e mantiveram-se e sobreviveram ao desafio letal. O Grupo Controle atingiu critérios de endpoint 96 h após a infecção. Estes resultados demonstram que uma vacina constituída de células inteiras de S. equi com rSeM protege camundongos contra adenite, sugerindo a capacidade de proteção a equinos e, possivelmente, superando as limitações das vacinas contra adenite atualmente disponíveis.

Immunogenicity of Streptococcus equi subsp. equi recombinant SeM protein and bacterin in mice / Imunogenicidade da proteína recombinante SeM de Streptococcus equi subsp. equi e da bacterina em camundongos

The infection caused by Streptococcus equi, known as strangles, affects the respiratory system of horses, causing high morbidity and rapid spread among the herd. Bacterin vaccines, composed of inactivated whole cells of S. equi, have variable efficacy and duration. Infected animals produce specific antibodies against SeM, the immunodominant antigen of S. equi. This makes it a promising target for vaccine development. In this context, the objective of this work was to evaluate a vaccine combining S. equi bacterin and recombinant SeM protein. Mice were vaccinated with bacterin (S. equi ~1.2 × 108CFU/ml); rSeM protein (20μg); bacterin-rSeM combination; or PBS (Control Group) and challenged with a suspension of S. equi, containing 10 × LD50. All vaccinated mice survived the challenge and produced anti-rSeM and anti-S. equi antibodies, which were assessed by indirect ELISA. The Control Group reached endpoint criteria 96 h after infection. These results demonstrate that a vaccine combining the S. equi bacterin with rSeM protein protects mice against strangles. This combination vaccine could potentially protect horses and overcome the limitations of currently available strangle vaccines.(AU)

A infecção causada por Streptococcus equi, denominada adenite, atinge o sistema respiratório de equinos, causando alta morbidade e rápida disseminação entre o rebanho. Vacinas bacterinas, compostas de células inteiras inativadas de S. equi apresentam eficácia e duração variáveis. Animais infectados apresentam anticorpos específicos à proteína SeM, antígeno imunodominante de S. equi, o que a torna um alvo promissor para o desenvolvimento de vacinas. Neste contexto, o objetivo deste trabalho foi avaliar uma vacina baseada na administração simultânea da bacterina e da proteína SeM recombinante. Camundongos foram vacinados com a bacterina (S. equi ~1.2 × 108CFU/ml); a proteína rSeM (20μg); a bacterina e rSeM simultaneamente; ou PBS (Grupo Controle) e, posteriormente, foram desafiados com uma suspensão de S. equi contendo 10 × LD50. Todos os animais vacinados apresentaram anticorpos anti-rSeM e contra S. equi, avaliados através de ELISA indireto, e mantiveram-se e sobreviveram ao desafio letal. O Grupo Controle atingiu critérios de endpoint 96 h após a infecção. Estes resultados demonstram que uma vacina constituída de células inteiras de S. equi com rSeM protege camundongos contra adenite, sugerindo a capacidade de proteção a equinos e, possivelmente, superando as limitações das vacinas contra adenite atualmente disponíveis.(AU)

Immunogenicity of Escherichia coli Expressing Streptococcus equi subsp. equi Recombinant SeM

Abstract The Equine Strangles, caused by Streptococcus equi subs. equi, is a contagious disease, causing high rates of morbidity been responsible for important economic losses. The M protein synthesized by S. equi plays an important role in the pathogenesis and is a promising candidate for a vaccine antigen. The innate immune system is responsible for the first immune response against microorganisms, this response is mediated by receptors that detect PAMPs and their activation trigger crucial modulation of the adaptative immune response. This work describes the immune response of S. equi subs. equi. recombinant SeM protein, using Escherichia coli BL21 (DE3) as an expression and delivery vaccine system. To characterize and to determine the vaccine efficacy, mice were vaccinated as followed: 1. Recombinant E. coli expressing rSeM protein; 2. The same recombinant E. coli, inactivated adsorbed in Alumen; 3. Purified rSeM protein adsorbed in Alumen; 4. Inactivated S. equi whole cells adsorbed in Alumen; 5. Control group. All vaccinated mice developed protective response against S. equi infection, however the groups that received the E. coli expressing rSeM presented significant higher IgG level than other vaccinated groups. The recombinant E. coli delivery vaccine system also induced a highest IgG response than inactivated S. equi or purified rSeM vaccines in horses. This study evidence that the recombinant E. coli, live or inactivated, enhanced the humoral response, reaching significant higher antibodies levels than those obtained in the vaccination with the bacterin or purified antigen, showing the feasibility of producing low-cost vaccines against strangles.